Showing 6201-6210 of 9139 results for "".
- EWG: UVA Protection of Most Sunscreens Just 25 Percent of Touted SPFhttps://practicaldermatology.com/news/ewg-most-sunscreens-comprise-just-25-percent-of-touted-spf/2460962/Many sunscreens offer just a quarter of their stated SPF protection against ultraviolet A rays, a new Environmental Working Group (EWG)
- Upsher-Smith Introduces Isotretinoin Capsules in UShttps://practicaldermatology.com/news/upsher-smith-introduces-isotretinoin-capsules-in-us/2460960/Isotretinoin capsules AB2-rated to the branded product Absorica® (isotretinoin) are now available in 10mg, 20mg, 30mg, and 40mg strengths from
- Study: Laser Plus Topical Steroids May Improve VLS Symptomshttps://practicaldermatology.com/news/study-laser-plus-topical-steroids-may-improve-vls-symptoms/2460959/Adding fractional CO2 laser treatments to topical steroids may maximize treatment outcomes in refractory vulvar lichen sclerosus (VLS), according to a new study in Lasers in Surgery and
- Study Seeks to Evaluate V. Dox Technology's Ability to Improve Healing Following HS Surgical Procedurehttps://practicaldermatology.com/news/study-seeks-to-evaluate-v-dox-technologys-ability-to-improve-healing-following-hs-surgical-procedure/2460958/The first patient has been enrolled in a new study using Vomaris Innovations, Inc.’s s bioelectric antimicrobial wound care technology following surgical treatment for Hidradenitis Suppurativa (HS). When tunnels develop under the skin in HS, a surgical procedure called deroofing i
- Study Highlights Skin Cancer Disparities in Hispanic/Latino Patientshttps://practicaldermatology.com/news/study-highlights-skin-cancer-disparities-in-hispaniclatino-patients/2460950/When Hispanic/Latino people are diagnosed with skin cancer, their tumors are 17 percent larger than tumors in non-Hispanic White patients, a new study shows. For the study, researchers analyzed a total of 3,486 Mohs micrographic surgeries of basal cell, squamous cell, and bas
- Safety Concerns Fuel Vaccine Hesitancy in PsO Patients on Biologics, But Data Fail to Show Increased Riskhttps://practicaldermatology.com/news/safety-concerns-fuel-vaccine-hesitancy-in-pso-patients-on-biologics-but-data-fail-to-show-increased-risk/2460947/Safety concerns and concerns about aggravation of their underlying condition are common drivers of COVID-19 vaccine hesitancy among patients with psoriatic disease, results of a new study show. Data come from an analysis of social media posts from patients in the US, UK, France, Germany, and
- Proscia's AI Technology Accurately Identifies Melanomas in Prospective Studyhttps://practicaldermatology.com/news/proscias-ai-technology-accurately-identifies-melanomas-in-prospective-study/2460944/Results of a prospective study just released demonstrate that an artificial intelligence (AI) technology solution from Proscia can automatically detect melanoma with a high degree of accuracy. Conducted at T
- Amgen/Kyowa Kirin's Anti-OX40 Shows Efficacy in Phase 2 for ADhttps://practicaldermatology.com/news/amgenkyowa-kirins-anti-ox40-shows-efficacy-in-phase-2-for-ad/2460943/Positive data from a Phase 2 study of AMG 451/KHK4083, presented at the European Academy of Dermatology and Venereology 30th Virtual Congress, show that the potential first-in-class anti-OX40 fully human monoclonal antibody in development for the treatment of moderate-to-severe atopic d
- PsO Improves Among Patients Who Switch to Janssen's Tremfya from Adalimumabhttps://practicaldermatology.com/news/pso-improves-among-patients-who-switch-to-janssens-tremfya-from-adalimumab/2460940/A total of 19 abstracts at the European Academy of Dermatology Venereology 30th Anniversary Congress will present data for Janssen’s Tremfya (guselkumab), including data showing an improvement in PASI response for psoriasis (PsO
- Updates from EADV: Cosentyx Autoinjector, Genetic Variants Linked to Genital Warts, At-Home PDT Shows Promisehttps://practicaldermatology.com/news/updates-from-eadv-cosentyx-autoinjector-genetic-variants-linked-to-genital-warts-at-home-pdt-shows-promise/2460939/• Treatment with Cosentyx®(secukinumab) 300mg in a 2mL autoinjector (UnoReady® pen) was more effective than placebo and achieved high patient satisfaction compared to two 150mg pre-filled syringes, according to Phase 3b data presented